Intervention Review

Laetrile treatment for cancer

  1. Stefania Milazzo1,*,
  2. Edzard Ernst2,
  3. Stephane Lejeune3,
  4. Katja Boehm1,
  5. Markus Horneber4

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 9 NOV 2011

Assessed as up-to-date: 1 SEP 2011

DOI: 10.1002/14651858.CD005476.pub3


How to Cite

Milazzo S, Ernst E, Lejeune S, Boehm K, Horneber M. Laetrile treatment for cancer. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD005476. DOI: 10.1002/14651858.CD005476.pub3.

Author Information

  1. 1

    Klinikum Nord, Medizinische Klinik 5-Schwerpunkt Onkologie/Haematologie, Nuernberg, Germany

  2. 2

    Peninsula Medical School, University of Exeter, Complementary Medicine Department, Exeter, UK

  3. 3

    EORTC, Data Centre, Brussels, Belgium

  4. 4

    Paracelsus Medical University, Klinikum Nuernberg, Department of Internal Medicine, Division of Oncology and Hematology, Nuernberg, Germany

*Stefania Milazzo, Medizinische Klinik 5-Schwerpunkt Onkologie/Haematologie, Klinikum Nord, Prof.-Ernst-Nathan-Str. 1, Nuernberg, D-90419, Germany. stesincro@yahoo.com. stesincro@yahoo.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 9 NOV 2011

SEARCH

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary

Background

Laetrile is the name for a semi-synthetic compound which is chemically related to amygdalin, a cyanogenic glycoside from the kernels of apricots and various other species of the genus Prunus. Laetrile and amygdalin are promoted under various names for the treatment of cancer although there is no evidence for its efficacy. Due to possible cyanide poisoning, laetrile can be dangerous.

Objectives

To assess the alleged anti-cancer effect and possible adverse effects of laetrile and amygdalin.

Search methods

We searched the following databases: CENTRAL (2011, Issue 1); MEDLINE (1951-2011); EMBASE (1980-2011); AMED; Scirus; CancerLit; CINAHL (all from 1982-2011); CAMbase (from 1998-2011); the MetaRegister; the National Research Register; and our own files. We examined reference lists of included studies and review articles and we contacted experts in the field for knowledge of additional studies. We did not impose any restrictions of timer or language.

Selection criteria

Randomized controlled trials (RCTs) and quasi-RCTs.

Data collection and analysis

We searched eight databases and two registers for studies testing laetrile or amygdalin for the treatment of cancer. Two review authors screened and assessed articles for inclusion criteria.

Main results

We located over 200 references, 63 were evaluated in the original review and an additional 6 in this update. However, we did not identify any studies that met our inclusion criteria.

Authors' conclusions

The claims that laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after laetrile or amygdalin, especially after oral ingestion. The risk–benefit balance of laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary

Laetrile treatment for cancer

Laetrile is a word created from the first letters of laevorotatory and mandelonitrile and describes a semi-synthetic form of amygdalin. Amygdalin is a compound that can be isolated from the seeds of many fruits such as peaches, bitter almonds and apricots. Both laetrile and amygdalin have a common structural component, mandelonitrile, that contains cyanide.

The lack of laetrile's effectiveness and the risk of side effects from cyanide poisoning led the Food and Drugs Agency (FDA) in the US and the European Commission to ban its use. However, it is possible to buy laetrile or amygdalin via the internet. As there is no government control of these markets, preparations may not only come from questionable sources but they may also be contaminated. Cancer patients should be informed about the high risk of developing serious adverse effects due to cyanide poisoning after laetrile or amygdalin, especially after oral ingestion. This risk could increase with concomitant intake of vitamin C and in vegetarians with vitamin B12 deficiency.

This systematic review found that there is no reliable evidence for the alleged effects of laetrile or amygdalin for curative effects in cancer patients.